In this study the LCx assay (a nucleic acid amplification assay) for Chlamydia 
KEY WORDS diagnostic tests; sensitivity; specificity hslamydia trachomatis (Ct) is the most common exually transmitted bacterial infection in the United States with an incidence of about 4-5% in the young adult population. 1 ,z It causes asymptomatic infections in as many as 25% of men 3, 4 and in 75% of women, s which leads to many undetected cases. It also leads to significant morbidity, giving a relative risk of ectopic pregnancy of 2.4-7.96 and causing epididymitis in approximately 3% of infected males. 7 These characteristics, and the fact that this disease is readily treatable make it an excellent candidate for a screening program. There are a variety of available methods with which to screen for Ct including culture, the Gen-Probe PACE2 assay (a nucleic acid probe assay), and more recently, LCx. The LCx assay which is based 13 .8% of patients with pyuria were positive for Ct whereas 9.3% of patients without pyuria were positive for Ct. Therefore it was of interest to compare the urine LCx results with the results obtained by the other detection methods in this subpopulation. The sensitivity/specificity in this subpopulation was 100/ 98.5% for LCx of endocervical samples, 50/100% for culture, and 33/100% for PACE2. Because of the smaller number of samples in the urine subpopulation, the differences between the urine subpopulation and the total population are probably not significant.
Our results indicate that LCx of endocervical samples had a much higher sensitivity than did the PACE2 assay or culture (which were the methods routinely used in our laboratory). Our limited data does not support routine substitution of midstream clean-catch urine samples for first-void urines in the LCx assay.
